Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,289 across all filing types
Latest filing 2026-06-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
瑞派宠物医院管理股份有限公司拟进行股权转让所涉及的天津中瑞供应链管理有限公司股东全部权益价值项目资产评估报告
Regulatory Filings Classification · 85% confidence The document is an asset valuation report (“资产评估报告”) prepared by an independent appraisal firm for an equity transfer transaction of Tianjin Zhongrui Supply Chain Management Co., Ltd. It contains detailed valuation methods, financial data, shareholding structures, and statutory filings with the China Asset Valuation Association. This is neither an annual or interim financial report, nor an earnings release, regulatory certification, proxy statement, share issuance notice, nor any other listed category. There is no specific category for independent asset appraisal reports, so under the fallback rules it should be classified as a general regulatory filing.
2026-06-10 Chinese
关于控股子公司及其下属子公司开展资产池业务并提供担保的公告
Capital/Financing Update Classification · 78% confidence The document is a public announcement by 瑞普生物股份有限公司 concerning its controlling subsidiary and sub-subsidiaries entering into an asset-pool financing arrangement with a bank (浙商银行) and providing guarantees up to specified limits. It details the nature, scope, counterparties, terms, limits, related parties, and financial data for this financing facility. This is not an annual report, earnings release, or board change; rather, it is an update on a financing activity. Therefore it fits the “Capital/Financing Update” category (CAP).
2026-06-10 Chinese
第六届董事会第五次（临时）会议决议公告
M&A Activity Classification · 75% confidence The document is a board resolution announcement (“董事会会议决议公告”) describing the approval of an equity acquisition (30% stake in a subsidiary) and the related-party transaction details, including voting results and compliance. It is a corporate transaction announcement rather than a simple management change or financial earnings release. The closest fit in our taxonomy is M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids, including equity acquisitions.
2026-06-10 Chinese
关于收购控股子公司天津中瑞供应链管理有限公司部分股权暨关联交易的公告
Regulatory Filings Classification · 72% confidence The document is an official regulatory announcement (“公告”) by 瑞普生物股份有限公司 regarding the acquisition of a 30% equity interest in its controlled subsidiary and related-party transaction details. It does not constitute a full financial report (e.g., 10-K, interim report), audit report, earnings release, or investor presentation, nor is it primarily about financing terms (CAP) or insider dealing. It is a standard regulatory disclosure of a corporate transaction that does not neatly fit into more specific categories, so it falls under the general “Regulatory Filings” category.
2026-06-10 Chinese
关于取得新兽药注册证书的公告
Regulatory Filings Classification · 89% confidence The document is a corporate announcement by 瑞普生物股份有限公司 regarding the receipt of new veterinary drug registration certificates from the Ministry of Agriculture and Rural Affairs. It details the certificate numbers, drug development background, and next steps before product launch. There are no financial statements, earnings data, management changes, share transactions, or meeting materials. It is a regulatory announcement about product approval, fitting the “Regulatory Filings” (RNS) category as a general compliance/regulatory announcement.
2026-06-05 Chinese
关于公司董事、总经理增持股份暨持股5%以上股东梁武之一致行动人转让股份的预披露公告
Director's Dealing Classification · 92% confidence The document is a formal pre-disclosure announcement of planned share transactions by a company director and general manager (Xu Lei) and a concerted actor of a >5% shareholder (Sheng Lina). It details insider trading plans (bulk share purchases and transfers), insider identity, percentages, timeframes, and legal compliance. This fits the definition of Director’s Dealing (insider share transactions by directors/executives).
2026-05-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.